tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Cytokinetics (CYTK) and Sarepta Therapeutics (SRPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHRResearch Report), Cytokinetics (CYTKResearch Report) and Sarepta Therapeutics (SRPTResearch Report).

United Therapeutics (UTHR)

BTIG analyst Julian Harrison maintained a Hold rating on United Therapeutics on August 3. The company’s shares closed last Thursday at $221.35.

According to TipRanks.com, Harrison is ranked 0 out of 5 stars with an average return of -13.2% and a 37.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Liquidia Technologies, and Keros Therapeutics.

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $253.00.

See today’s best-performing stocks on TipRanks >>

Cytokinetics (CYTK)

JMP Securities analyst Jason Butler reiterated a Buy rating on Cytokinetics today and set a price target of $53.00. The company’s shares closed last Thursday at $46.72, close to its 52-week high of $49.41.

According to TipRanks.com, Butler is ranked 0 out of 5 stars with an average return of -8.8% and a 39.6% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $65.20 average price target, a 49.5% upside from current levels. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $64.00 price target.

Sarepta Therapeutics (SRPT)

BTIG analyst Yun Zhong reiterated a Buy rating on Sarepta Therapeutics on August 3 and set a price target of $125.00. The company’s shares closed last Thursday at $101.45.

According to TipRanks.com, Zhong ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.4% and a 30.8% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Applied Genetic Technologies, and Mereo Biopharma Group Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $129.63 average price target, implying a 34.8% upside from current levels. In a report issued on July 29, Needham also maintained a Buy rating on the stock with a $162.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More